Product Information
ZARXIO 480 MCG/0.8 ML SYRINGE is a brand biologic product labeled by Sandoz Inc., priced at $533.4125 per ML under NDC 61314032601. Its NADAC has been published 129 times since Apr 17, 2024.
Strength
480 ug/.8mL
Manufacturer
Sandoz Inc.NDC
61314032601
Classification
Brand Biologic
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS; SUBCUTANEOUS
Effective Date
12/17/2025
Active Ingredients
FILGRASTIMApproval Type
Biologic (BLA)
FDA Application
BLA125553On Market Since
3/6/2015
Pharmacological Classes
Price Statistics
The NADAC for ZARXIO 480 MCG/0.8 ML SYRINGE has been published 129 times since Apr 17, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $533.4125 per ML |
|---|---|
| All-time high | $533.4125 (Sep 30, 2026) |
| All-time low | $528.1771 (May 22, 2024) |
| 52-week high | $533.4125 |
| 52-week low | $533.1097 |
| Median price | $532.8719 |
| Average price | $531.7588 |
| Largest weekly change | -0.3% (May 22, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the filgrastim-sndz market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sandoz Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
filgrastim-sndz market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Leukocyte Growth Factor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZARXIO 480 MCG/0.8 ML SYRINGE?
The current National Average Drug Acquisition Cost (NADAC) for ZARXIO 480 MCG/0.8 ML SYRINGE, manufactured by Sandoz Inc., is $533.4125 per ML (NDC 61314032601), effective Sep 30, 2026.
How has the price of ZARXIO 480 MCG/0.8 ML SYRINGE changed over time?
Over the history we have for it, the NADAC for ZARXIO 480 MCG/0.8 ML SYRINGE has held within roughly two percent of its current level. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for ZARXIO 480 MCG/0.8 ML SYRINGE?
Since Apr 17, 2024, the NADAC for ZARXIO 480 MCG/0.8 ML SYRINGE has ranged from a low of $528.1771 (May 22, 2024) to a high of $533.4125 (Sep 30, 2026), with a median of $532.8719 per ML.
Are there cheaper alternatives to ZARXIO 480 MCG/0.8 ML SYRINGE?
No other NADAC-published product currently shares the active ingredient and strength of ZARXIO 480 MCG/0.8 ML SYRINGE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ZARXIO 480 MCG/0.8 ML SYRINGE?
ZARXIO 480 MCG/0.8 ML SYRINGE (NDC 61314032601) is labeled by Sandoz Inc., and CMS classifies it as a brand biologic product.